Surgery Versus Intra-lesional Sclerosis With Polidocanol (Aetoxisclerol) in Labial Venous Malformations in Children and Adults (SASOV)
Surgery Versus Intra-lesional Sclerosis With Polidocanol (Aetoxisclerol) in Labial Venous Malformations in Children and Adults: a Randomized Controlled Trial
The goal of this clinical trial is to learn if Surgery works better than Intra-lesional Sclerosis With Polidocanol to treat Labial Venous Malformations in Children and Adults. It will also learn about the safety of both approaches. The main questions it aims to answer are:
- Does Surgery has greater Global efficacy, including (including lesion volume reduction, scar quality, and lip symmetry) than Intra-lesional Sclerosis With Polidocanol?
- What complications do participants have when undergoing Surgery or Intra-lesional Sclerosis With Polidocanol? Researchers will compare surgery to Intra-lesional Sclerosis With Polidocanol.
Participants will be randomized to one of two treatment strategies:
- Experimental group: Surgical excision of the labial venous malformation (VM).
- Control group: Sclerotherapy strategy consisting of one or two sessions of intralesional polidocanol 3% injection.
Patients will be identified and recruited during multidisciplinary vascular anomalies clinics. The study protocol will be explained to eligible patients and their families. After obtaining written informed consent (or consent from both parents together with the child's assent, when applicable), participants will be enrolled in the study.
Following enrollment, participants will be randomly assigned to one of the two parallel treatment groups. A baseline assessment will be performed, and patients will receive a patient diary to record subjective outcomes, including pain, during the pre-intervention period until the date of the procedure.
Study follow-up visits will take place at 1 month (telemedicine visit), 3 months, and 12 months after treatment. Outcome assessments will be performed at each scheduled follow-up visit.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Aline JOLY, MD
- Numéro de téléphone: +332 47 47 38 21
- E-mail: a.joly@chu-tours.fr
Sauvegarde des contacts de l'étude
- Nom: Coralie TAILLEBUIS
- Numéro de téléphone: +33247473909
- E-mail: c.taillebuis@chu-tours.fr
Lieux d'étude
-
-
-
Paris, France
- Lariboisière
-
Contact:
- Annouk BISDORFF, MD
- Numéro de téléphone: +331 49 95 84 50
- E-mail: annouk.bisdorff@aphp.fr
-
Contact:
- E-mail: a.joly@chu-tours.fr
-
Chercheur principal:
- Annouk BISDORFF, MD
-
Paris, France
- Necker
-
Contact:
- Olivia BOCCARA, MD
- Numéro de téléphone: +331 44 49 46 63
- E-mail: olivia.boccara@aphp.fr
-
Chercheur principal:
- Olivia BOCCARA, MD
-
Tours, France
- CHRU de Tours
-
Contact:
- Aline JOLY, MD
- Numéro de téléphone: +332 47 47 38 21
- E-mail: a.joly@chu-tours.fr
-
Contact:
- E-mail: a.joly@chu-tours.fr
-
Chercheur principal:
- Aline JOLY, MD
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age ≥ 4 years
- Symptomatic venous malformation of the lower and/or upper lip
- Venous pocket with an area of between 10 and 50 mm²
- No history of surgery or interventional radiology in the area within the two years prior to inclusion
- Suitable for sclerotherapy and surgery
- Patient covered by the National Health Service
- Informed, written consent from the child's legal guardians or from the participant themselves if they are of legal age
Exclusion Criteria:
- Pregnant or breastfeeding women
- Women of childbearing age not using effective contraception throughout the study
- Patients under guardianship or curatorship, or subject to a court-ordered protective measure
- Other vascular abnormalities
- Contraindications to MRI
- Contraindications to Aetoxisclerol®
- Contraindications to general anaesthesia
- Contraindications to surgery
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Surgical strategy
Experimental group: Surgical strategy for the excision of the superficial venous malformation (SVM). The surgery involves either partial reconstructive excision or complete excision of the SVM, depending on its size. The aim is to restore symmetry to the affected side of the lip in order to correct functional impairments and aesthetic effects. |
The surgery is performed under local or general anaesthesia (depending on the size of the SVM and the patient's age). Various coagulation devices (monopolar forceps with a Colorado tip, bipolar scissors, etc.) are used to section and dissect the SVM and to control haemostasis. |
|
Comparateur actif: Sclerotherapy strategy
Control group: Sclerotherapy strategy comprising one to two sessions of intra-lesional sclerotherapy with 3% polidocanol (Aetoxisclerol). |
The procedure may be carried out under local or general anaesthesia, depending on the patient's age, anticipated tolerance and in accordance with standard practice at the centre. The patient is positioned in the supine position. Following manual and visual localisation of the target lesion, one or more needles of 30/100th to 18G gauge are inserted, and their position within the lesion is confirmed by gentle aspiration, which should yield blood without resistance. The injection of an iodinated contrast medium suitable for intravenous use, to characterise the drainage and under fluoroscopic guidance in the angiography suite, is recommended but not mandatory. Once in place, ≤ 2 mg/kg of polidocanol is injected per session, i.e. ≤ 0.067 mL/kg of 3% solution distributed amongst the needles (1/2 to 2 ampoules), until thrombosis occurs, significant tension is felt in the lesion, or pain develops. Sclerotherapy may be repeated if necessary between 3 and 6 months after the first session. |
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Global change
Délai: From enrollment to Month 12 post intervention
|
Global change will be assessed 12 months after the intervention using a Likert scale ranging from -5 to +5 (0 = no improvement or worsening, higher scores mean better outcome), based on standardized pre- and post-intervention photographs. Assessments will be performed by an independent review panel comprising three physicians (one surgeon, one dermatologist, and one interventional radiologist) and one patient with a labial VM who did not participate in the study. The evaluation will be performed blinded to treatment allocation and will encompass changes in lesion volume, scar quality, and lip symmetry. A standardized photography protocol will be used. This primary endpoint (photograph-based assessment by an independent review panel) was selected to limit bias related to the open-label nature of the study, consistent with a PROBE design (Prospective Randomized Open, Blinded Endpoint). |
From enrollment to Month 12 post intervention
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Aesthetic impact of the venous malformation
Délai: Month 0 and Month 12
|
Assessment of aesthetic burden using a 0 to 10 visual analogue scale (VAS) with higher scores mean worse outcome, measured at baseline and 12 months after the intervention. |
Month 0 and Month 12
|
|
Functional impact: overall mouth function
Délai: Month 0 and Month 12
|
Functional impact assessed using a 0 to 10 Visual Analogue Scale (VAS) for overall mouth function, with higher scores mean worse outcome |
Month 0 and Month 12
|
|
Functional impact: lip continence
Délai: Month 0 and Month 12
|
Quantification of lip continence using a self-administered drooling questionnaire (Drooling Severity and Frequency Scale [DSFS]), score ranging from 2 to 9 with higher scores mean worse outcome |
Month 0 and Month 12
|
|
Functional impact: speech intelligibility
Délai: Month 0 and Month 12
|
Speech intelligibility assessed using a self-administered questionnaire measuring speech-related intelligibility, the Intelligibility in Context Scale (ICS). Score ranging from 7 to 35, with higher scores mean better outcome |
Month 0 and Month 12
|
|
Overall patient satisfaction: Likert scale
Délai: From enrollment to Month 12
|
Overall patient satisfaction assessed with a Likert scale ranging from -5 to +5 (0 = no improvement and no worsening), higher scores mean better outcome |
From enrollment to Month 12
|
|
Overall patient satisfaction: Goal Attainment Scale
Délai: Month 12
|
Using achievement of personalized goals (maximum of three), predefined by the patient together with the investigator, assessed with the Goal Attainment Scale (GAS; scores ranging from -2 to +2, with higher scores mean better outcome). The Goal Attainment Scale (GAS) is a method for measuring treatment effectiveness by creating patient-specific outcome scales that are predefined before study participation. GAS aims to identify goals that are meaningful to the patient and related to their daily activities and individual priorities (Steinbook RM, 1977; DOI: 10.1001/archpsyc.1977.01770200061005). |
Month 12
|
|
Number of painful days: Total number of painful days
Délai: The month (30 days) preceding the intervention, the month following the intervention, and the month preceding the 12-month post intervention visit (M12)
|
Total number of painful days assessed using either a patient diary or the online ePRO portal. |
The month (30 days) preceding the intervention, the month following the intervention, and the month preceding the 12-month post intervention visit (M12)
|
|
Number of painful days: Number of painful days with a VAS pain score > 3/10
Délai: The month (30 days) preceding the intervention, the month following the intervention, and the month preceding the 12-month post-intervention visit (M12)
|
Number of painful days with a VAS pain score > 3/10 assessed using either a patient diary or the online ePRO portal. |
The month (30 days) preceding the intervention, the month following the intervention, and the month preceding the 12-month post-intervention visit (M12)
|
|
Venous Malformation volume on MRI
Délai: Month 0 and Month 12
|
Venous malformation volume assessed before the intervention (within 6 months prior to treatment) and 12 months after the intervention (performed as part of routine care). Volumetric assessment will be conducted using a semi-automated thresholding method. Image analysis will be centralized and performed by an independent radiologist blinded to treatment allocation. |
Month 0 and Month 12
|
|
Coagulation: D-dimer
Délai: Month 12
|
D-dimer |
Month 12
|
|
Coagulation: fibrinogen level
Délai: Month 12
|
Fibrinogen level |
Month 12
|
|
Adverse events including complications
Délai: From enrollment to Month 12
|
Safety including adverse events and complications, recorded using a patient diary or the online ePRO portal |
From enrollment to Month 12
|
|
Acceptability of the interventions
Délai: Month 1, Month 3 , and Month 12
|
Acceptability of the interventions for the patient (or for parents in children aged < 6 years), assessed using a 0 to 10 Visual Analogue Scale (VAS), with higher scores mean worse outcome |
Month 1, Month 3 , and Month 12
|
|
Healthcare costs
Délai: From enrollment to Month 12 following the intervention
|
In each arm, patients' healthcare utilization related to the procedure and outpatient care will be measured using hospital databases and a patient diary, then valued in euros from the perspective of the healthcare system. |
From enrollment to Month 12 following the intervention
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- DR240317
- 2025 (Subvention/contrat des NIH des États-Unis)
- 2025-521374-34-00 (Ctis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .